- Home
- RTO vs EXAS Comparison
RTO vs EXAS Comparison
Compare RTO & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RTO
- EXAS
- Stock Information
- Founded
- RTO 1925
- EXAS 1995
- Country
- RTO United Kingdom
- EXAS United States
- Employees
- RTO N/A
- EXAS N/A
- Industry
- RTO Business Services
- EXAS Medical Specialities
- Sector
- RTO Consumer Discretionary
- EXAS Health Care
- Exchange
- RTO Nasdaq
- EXAS Nasdaq
- Market Cap
- RTO 12.0B
- EXAS 10.2B
- IPO Year
- RTO N/A
- EXAS N/A
- Fundamental
- Price
- RTO $25.64
- EXAS $55.61
- Analyst Decision
- RTO Hold
- EXAS Strong Buy
- Analyst Count
- RTO 1
- EXAS 22
- Target Price
- RTO N/A
- EXAS $67.38
- AVG Volume (30 Days)
- RTO 758.1K
- EXAS 3.0M
- Earning Date
- RTO 07-31-2025
- EXAS 11-04-2025
- Dividend Yield
- RTO 2.21%
- EXAS N/A
- EPS Growth
- RTO N/A
- EXAS N/A
- EPS
- RTO 0.13
- EXAS N/A
- Revenue
- RTO $7,581,860,530.00
- EXAS $2,939,949,000.00
- Revenue This Year
- RTO $13.39
- EXAS $16.50
- Revenue Next Year
- RTO $2.81
- EXAS $12.32
- P/E Ratio
- RTO $191.95
- EXAS N/A
- Revenue Growth
- RTO N/A
- EXAS 12.55
- 52 Week Low
- RTO $19.60
- EXAS $38.81
- 52 Week High
- RTO $27.37
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- RTO 59.36
- EXAS 71.32
- Support Level
- RTO $25.30
- EXAS $46.30
- Resistance Level
- RTO $25.97
- EXAS $56.52
- Average True Range (ATR)
- RTO 0.40
- EXAS 1.57
- MACD
- RTO 0.11
- EXAS 1.02
- Stochastic Oscillator
- RTO 86.36
- EXAS 91.83
About RTO Rentokil Initial plc
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in 89 countries. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.